Ascendis Pharma (ASND) CFO lists warrants, RSUs and shares

Rhea-AI Filing Summary

Ascendis Pharma A/S executive vice president and chief financial officer Scott Thomas Smith filed an initial statement of ownership showing a mix of direct equity and derivative awards linked to the company’s ordinary shares and American Depositary Shares.

He holds warrants over 45,000 ordinary shares at an exercise price of $37.18 expiring on December 12, 2027, another 45,000 at $62.17 expiring on December 11, 2028, 27,000 at $108.00 expiring on December 10, 2029, 22,755 at $176.28 expiring on December 10, 2030, and 14,504 at $139.65 expiring on December 9, 2031. These warrants are fully vested and currently exercisable. He also holds restricted stock units covering 4,246, 3,197 and 9,552 ordinary shares, which vest beginning on March 1, 2027, and 2,517 ordinary shares outright. Each ordinary share is represented by one ADS.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SMITH SCOTT THOMAS

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP DK-2900

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	2,517	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	(2)	12/12/2027	Ordinary Shares	45,000	$37.18	D
Warrants	(2)	12/11/2028	Ordinary Shares	45,000	$62.17	D
Warrants	(2)	12/10/2029	Ordinary Shares	27,000	$108	D
Warrants	(2)	12/10/2030	Ordinary Shares	22,755	$176.28	D
Warrants	(2)	12/09/2031	Ordinary Shares	14,504	$139.65	D
Restricted Stock Units	(3)	(3)	Ordinary Shares	4,246	(4)	D
Restricted Stock Units	(5)	(5)	Ordinary Shares	3,197	(4)	D
Restricted Stock Units	(6)	(6)	Ordinary Shares	9,552	(4)	D

Explanation of Responses:

1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.

2. The warrants are fully vested and currently exercisable.

3. The restricted stock units vest on March 1, 2027 and have no expiration date.

4. Each restricted stock unit represents a contingent right to receive one ADS.

5. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.

6. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

	/s/ Michael Wolff Jensen as attorney-in-fact for Scott Smith	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Ascendis Pharma (ASND) Form 3 filing show for CFO Scott Thomas Smith?

The Form 3 shows Scott Thomas Smith’s initial ownership in Ascendis Pharma, including warrants, restricted stock units, and ordinary shares. It outlines exercise prices, expiration dates, and vesting schedules tied to ordinary shares represented by American Depositary Shares.

How many warrants tied to Ascendis Pharma (ASND) shares does the CFO hold?

Scott Thomas Smith holds warrants over several blocks of ordinary shares: 45,000 at $37.18, 45,000 at $62.17, 27,000 at $108.00, 22,755 at $176.28, and 14,504 at $139.65. All these warrants are fully vested and currently exercisable.

What restricted stock units does the Ascendis Pharma (ASND) CFO report?

He reports three restricted stock unit grants covering 4,246, 3,197 and 9,552 ordinary shares. These units have a zero exercise price and vest beginning on March 1, 2027, in scheduled annual installments, providing future rights to receive one ADS per unit.

When do Scott Thomas Smith’s Ascendis Pharma (ASND) RSUs vest?

One RSU grant vests on March 1, 2027, with no expiration date. Additional RSU grants vest in two or three equal annual installments beginning on March 1, 2027, giving him contingent rights to receive American Depositary Shares over time.

How many Ascendis Pharma (ASND) ordinary shares does the CFO hold directly?

The filing shows Scott Thomas Smith directly holding 2,517 ordinary shares. The footnotes clarify that these include American Depositary Shares, with each ADS representing one ordinary share of Ascendis Pharma A/S.

Are the Ascendis Pharma (ASND) CFO’s warrants already exercisable?

Yes. The footnotes state that all reported warrants held by Scott Thomas Smith are fully vested and currently exercisable. Each warrant series has its own exercise price and expiration date between December 2027 and December 2031.